國軒高科(002074.SZ):與大眾共同開發的標準電芯C樣正在緊鑼密鼓的驗證過程中
格隆匯2月26日丨國軒高科(002074.SZ)在投資者互動平台表示,國軒高科與大眾共同開發的標準電芯C樣正在緊鑼密鼓的驗證過程中。該產品在國軒高科合肥基地的批量生產時間將根據大眾的產品路線圖最終確定。基於與大眾集團的合作,國軒高科正以最新的技術加速標準電芯的產品迭代,以實現雙方最大的靈活性和成本效益。大眾中國是國軒高科的戰略投資者,大眾汽車集團(中國)與寧德時代的諒解備忘錄不會影響與國軒高科的合作,雙方的合作正在按計劃推進中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.